Resectable, borderline resectable, and locally advanced pancreatic cancer: What does it matter? Topical collection on gastrointestinal cancers

Current Oncology Reports

Volumn 16, Issue 2, 2014, Pages

  Halperin, Daniel M ^a   Varadhachary, Gauri R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Borderline; Borderline resectable pancreatic cancer; Gastrointestinal cancers; Localized pancreatic cancer; Neoadjuvant; Pancreatic adenocarcinoma; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; BILIARY DECOMPRESSION; BORDERLINE RESECTABLE PANCREATIC CANCER; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DECOMPRESSION; HUMAN; OUTCOME ASSESSMENT; PANCREAS CANCER; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STANDARDIZATION; ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); METHODOLOGY; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; REVIEW;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84899448568     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-013-0366-9     Document Type: Article

References (71)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30. doi: 10.3322/caac.21166.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049-57. doi: 10.1016/S0140-6736(04)15841-8.
3. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225(5):621-33.
4. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128-37. doi: 10.1056/NEJMsa012337.
5. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349(22):2117-27. doi: 10.1056/NEJMsa035205.
6. Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2004;8(8):935-49. doi: 10.1016/j.gassur.2004.09.046. discussion 49-50.
7. Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, et al. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010;101(7):587-92. doi: 10.1002/jso.21527.
8. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson 3rd AB, Casper ES, et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. JNCCN. 2012;10(6):703-13.
9. Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR. 1997;168(6):1439-43. doi: 10.2214/ajr.168.6.9168704.
10. Mehta VK, Fisher G, Ford JA, Poen JC, Vierra MA, Oberhelman H, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2001;5(1):27-35.
11. Allema JH, Reinders ME, van Gulik TM, van Leeuwen DJ, de Wit LT, Verbeek PC, et al. Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head. Br J Surg. 1994;81(11):1642-6.
12. Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Buchler MW, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 2011;254(6):882-93. doi: 10.1097/SLA.0b013e31823ac299.
13. Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, et al. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012;19(6):2045-53. doi: 10.1245/s10434-011-2211-4.
14. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267-77. doi: 10.1001/jama.297.3.267.
15. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200-10. doi: 10.1056/ NEJMoa032295.
16. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073-81. doi: 10.1001/jama.2010.1275.
17. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299(9):1019-26. doi: 10.1001/jama.299.9.1019.
18. Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010;17(4):981-90. doi: 10.1245/s10434-009-0743-7.
19. Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(21):3503-10. doi: 10.1200/JCO.2007.15. 8469.
20. Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(21):3511-6. doi: 10.1200/JCO.2007.15.8782.
21. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987;59(12):2006-10.
22. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899-903.
23. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(21):3496-502. doi: 10.1200/JCO.2007.15.8634.
24. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(21):3487-95. doi: 10.1200/JCO.2007.15. 8642.
25. • Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LA, Griffith KA, et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013. doi: 10.1002/cncr.28117. This recent study demonstrated improved R0 resection rates with neoadjuvant therapy, but no improvement in overall survival, compared to historical controls.
26. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981;48(8):1705-10.
27. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267. doi: 10.1371/journal.pmed.1000267.
28. • Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14(4):317-26. doi: 10.1016/s1470-2045(13)70021-4. This recent study showed potential benefit of capecitabine-based chemoradiation over gemcitabine-based chemoradiation in the secondary endpoint of median overall survival for patients with unresectable pancreatic adenocarcinoma, following induction chemotherapy.
29. Hammel P, Huguet F, Van Laethem J, Goldstein D, Glimelius B, Artru P et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31 suppl:abstr LBA4003.
30. •• Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20(8):2787-95. doi: 10.1245/s10434-013-2886-9. This recent review article discusses the construction of the Alliance Trial.
31. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749-56. doi: 10.1002/cncr.27636.
32. Kang CM, Chung YE, Park JY, Sung JS, Hwang HK, Choi HJ, et al. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2012;16(3):509-17. doi: 10.1007/s11605-011-1784-3.
33. Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199. doi: 10.1186/1471-2407-12-199.
34. Barugola G, Partelli S, Crippa S, Capelli P, D'Onofrio M, Pederzoli P, et al. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 2012;203(2):132-9. doi: 10.1016/j.amjsurg.2011.03.008.
35. Takahashi S, Kinoshita T, Konishi M, Gotohda N, Kato Y, Kobayashi T, et al. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. J Hepato-Biliary-Pancreat Sci. 2011;18(4):567-74. doi: 10.1007/s00534-011-0371-z.
36. Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011;18(3):619-27. doi: 10.1245/s10434-010- 1456-7.
37. Chuong MD, Hayman TJ, Patel MR, Russell MS, Malafa MP, Hodul PJ, et al. Comparison of 1-, 2-, and 3-dimensional tumor response assessment after neoadjuvant GTX-RT in borderline-resectable pancreatic cancer. GCR. 2011;4(4):128-34.
38. Arvold ND, Niemierko A, Mamon HJ, Fernandez-del Castillo C, Hong TS. Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys. 2011;80(5):1383-90. doi: 10.1016/j.ijrobp.2010.04.058.
39. McClaine RJ, Lowy AM, Sussman JJ, Schmulewitz N, Grisell DL, Ahmad SA. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB Off J Int Hepato Pancreato Biliary Assoc. 2010;12(1):73-9. doi: 10.1111/j.1477-2574.2009. 00136.x.
40. Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, et al. Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol. 2010;17(11):2832-8. doi: 10.1245/s10434-010-1284-9.
41. Turrini O, Viret F, Moureau-Zabotto L, Guiramand J, Moutardier V, Lelong B, et al. Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2009;35(12):1306-11. doi: 10.1016/j.ejso.2009.06. 005.
42. Satoi S, Yanagimoto H, Toyokawa H, Takahashi K, Matsui Y, Kitade H, et al. Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas. 2009;38(3):282-8. doi: 10.1097/MPA. 0b013e31819438c3.
43. Brown KM, Siripurapu V, Davidson M, Cohen SJ, Konski A, Watson JC, et al. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg. 2008;195(3):318-21. doi: 10.1016/j.amjsurg.2007.12.017.
44. Massucco P, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol. 2006;13(9):1201-8. doi: 10.1245/s10434-006-9032-x.
45. Leone F, Gatti M, Massucco P, Colombi F, Sperti E, Campanella D, et al. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer. 2013;119(2):277-84. doi: 10.1002/cncr.27736.
46. • Lee JL, Kim SC, Kim JH, Lee SS, Kim TW, Park do H, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery. 2012;152(5):851-62. doi: 10.1016/j.surg.2012.03.010. This study was able to demonstrate excellent R0 rates with neoadjuvant therapy, though patient groups were defined with a proprietary classification system, and not analyzed separately.
47. Sahora K, Kuehrer I, Schindl M, Koelblinger C, Goetzinger P, Gnant M. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg. 2011;35(7):1580-9. doi: 10.1007/s00268-011-1113-8.
48. Sahora K, Kuehrer I, Eisenhut A, Akan B, Koellblinger C, Goetzinger P, et al. NeoGemOx: gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery. 2011;149(3):311-20. doi: 10.1016/j.surg.2010.07.048.
49. Small Jr W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(6):942-7. doi: 10.1200/JCO.2007.13.9014.
50. Pipas JM, Barth Jr RJ, Zaki B, Tsapakos MJ, Suriawinata AA, Bettmann MA, et al. Docetaxel/gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol. 2005;12(12):995-1004. doi: 10.1245/ASO.2005.04.503.
51. Zimmermann FB, Schuhmacher C, Lersch C, Bernhardt B, Pickel P, Siewert JR, et al. Sequential and/or concurrent hypofractionated radiotherapy and concurrent chemotherapy in neoadjuvant treatment of advanced adenocarcinoma of the pancreas. Outcome and patterns of failure. Hepato-Gastroenterology. 2004;51(60):1842-6.
52. • Motoi F, Ishida K, Fujishima F, Ottomo S, Oikawa M, Okada T, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol. 2013. doi: 10.1245/s10434-013-3129-9. This study of neoadjuvant therapy demonstrated excellent R0 and survival rates, though the population was defined with a proprietary system including less threatening anatomy than most widely-accepted systems.
53. Jinkins LJ, Parmar AD, Han Y, Duncan CB, Sheffield KM, Brown KM, et al. Current trends in preoperative biliary stenting in patients with pancreatic cancer. Surgery. 2013;154(2):179-89. doi: 10.1016/j.surg.2013.03.016.
54. Ross WA, Wasan SM, Evans DB, Wolff RA, Trapani LV, Staerkel GA, et al. Combined EUS with FNA and ERCP for the evaluation of patients with obstructive jaundice from presumed pancreatic malignancy. Gastrointest Endosc. 2008;68(3):461-6. doi: 10.1016/j.gie.2007.11.033.
55. Gress F, Michael H, Gelrud D, Patel P, Gottlieb K, Singh F, et al. EUS-guided fine-needle aspiration of the pancreas: evaluation of pancreatitis as a complication. Gastrointest Endosc. 2002;56(6):864-7. doi: 10.1067/mge.2002.129602.
56. Mullen JT, Lee JH, Gomez HF, Ross WA, Fukami N, Wolff RA, et al. Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2005;9(8):1094-104. doi: 10.1016/j.gassur.2005.08.006. discussion 104-5.
57. Kozarek R. Role of preoperative palliation of jaundice in pancreatic cancer. J Hepato-Biliary-Pancreat Sci. 2013. doi: 10.1007/s00534-013-0612-4.
58. Lee JH, Krishna SG, Singh A, Ladha HS, Slack RS, Ramireddy S, et al. Comparison of the utility of covered metal stents versus uncovered metal stents in the management of malignant biliary strictures in 749 patients. Gastrointest Endosc. 2013;78(2):312-24. doi: 10.1016/j.gie.2013.02.032.
59. Bruno MJ, Haverkort EB, Tijssen GP, Tytgat GN, van Leeuwen DJ. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut. 1998;42(1):92-6.
60. Gooden HM, White KJ. Pancreatic cancer and supportive care-pancreatic exocrine insufficiency negatively impacts on quality of life. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2013;21(7):1835-41. doi: 10.1007/s00520-013-1729-3.
61. Shinkawa H, Takemura S, Uenishi T, Sakae M, Ohata K, Urata Y, et al. Nutritional risk index as an independent predictive factor for the development of surgical site infection after pancreaticoduodenectomy. Surg Today. 2013;43(3):276-83. doi: 10.1007/s00595-012-0350-2.
62. La Torre M, Ziparo V, Nigri G, Cavallini M, Balducci G, Ramacciato G. Malnutrition and pancreatic surgery: prevalence and outcomes. J Surg Oncol. 2013;107(7):702-8. doi: 10.1002/jso.23304.
63. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-25. doi: 10.1056/NEJMoa1011923.
64. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-703. doi: 10.1056/NEJMoa1304369.
65. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271(5247):350-3.
66. Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(14):4674-9. doi: 10.1158/1078-0432.CCR-09-0227.
67. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(11):1806-13. doi: 10.1200/JCO.2008.17.7188.
68. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500-3. doi: 10.1038/nm.2344.
69. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828-33. doi: 10.1097/CJI.0b013e3181eec14c.
70. Niu L, Chen J, He L, Liao M, Yuan Y, Zeng J, et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer. Pancreas. 2013. doi: 10.1097/MPA.0b013e3182965dde.
71. DeVito NC, Saif MW. Advances in immunotherapy for pancreatic cancer: 2013. JOP. 2013;14(4):347-53. doi: 10.6092/1590-8577/1646.